Scribe Therapeutics, a gene editing biotech co-founded by CRISPR pioneer Jennifer Doudna, has priced a $129 million initial public offering on Nasdaq. Trading under the ticker SCTX, the debut marks a notable moment for biotech listings as the year moves into its second half.
The company, now nine years old, arrives on the public markets with the profile of a next-generation gene editor and a prominent scientific pedigree. Its offering is drawing attention not only for its size, but also for the founders behind the platform.
Scribe’s listing helps open what is expected to be a busier stretch for biotech IPOs in the coming weeks. Industry watchers anticipate a cluster of six additional biotech offerings to follow, suggesting renewed momentum for new issues after a quieter period.
How SCTX performs out of the gate will be closely watched as a potential indicator for investor appetite toward upcoming biotech debuts. For now, Scribe’s $129 million raise sets the tone for the sector’s second-half IPO calendar.
